Sign in
WithdrawnPhase 1/2

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Key facts

Who runs it
New York State Psychiatric Institute
Where
New York, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Mar 2022
Ended
8 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nabilone
  • Placebo
Record updated
21 May 2024
Why it stopped
The Principal Investigator is no longer at the Institution and a request for early termination of the grant supporting the study was submitted to NIH.

Who can take part

Age
21 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Between 21-55 years of age
  • Physically healthy and, if female, not pregnant
  • Able to tolerate all study procedures
  • Able to provide written informed consent to participate
  • Right-handed
  • Primary diagnosis of OCD
  • Not taking psychotropic medications or other substances likely to interact with nabilone

Who cannot take part

  • History of receiving cognitive behavior or exposure-based psychotherapy in the past 3 months
  • History of any significant medical condition that may increase the risk of participation
  • Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder)
  • Current substance use disorder
  • Any history of adverse reaction to a cannabinoid
  • History of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
  • History of claustrophobia or unable to tolerate confined spaces like an MRI
  • Females who are pregnant or nursing
  • Positive urine toxicology or alcohol breathalyzer

Where in United States

  • New York State Psychiatric InstituteNew York, United States

About the trial

What the trial wants to find out

The purpose of this research study is to test how a medication called nabilone (Cesamet) affects neurocognitive processes involved in obsessive-compulsive disorder (OCD), including threat response, processing of fear signals, and habitual behavior. OCD is a disabling illness that affects around 2% of the population and involves recurrent intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that lead to distress and/or impaired functioning. Nabilone is a synthetic form of delta-9-tetrahydrocannabinol (THC, the primary psychoactive component of the cannabis plant). It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD symptoms. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.

Read full original descriptionShow less

In this study, 60 adults with OCD will receive a single dose of either nabilone or placebo. Participants will then complete a series of assessments including neuroimaging, psychophysiology (e.g., skin conductance recording), computerized behavioral tasks, and self-report measures. The information gained from this study could contribute to the development of new treatments for people with OCD and related disorders.

The 2 groups in the trial

  • NabiloneExisting treatment, for comparison

    In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.

  • PlaceboPlacebo, for comparison

    In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
21 May 2024